{"id":2338,"date":"2020-07-08T00:00:00","date_gmt":"2020-07-08T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2338"},"modified":"2020-07-08T00:00:00","modified_gmt":"2020-07-08T00:00:00","slug":"a-centogene-anuncia-proposta-de-oferta-publica-primaria-e-secundaria-de-acoes-ordinarias","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pt\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/","title":{"rendered":"A CENTOGENE anuncia proposta de oferta p\u00fablica prim\u00e1ria e secund\u00e1ria de a\u00e7\u00f5es ordin\u00e1rias."},"content":{"rendered":"<p>CAMBRIDGE, Massachusetts, ROSTOCK, Alemanha e BERLIM, 7 de julho de 2020 (Globe Newswire) \u2013 A Centogene NV (Nasdaq: CNTG), empresa em fase comercial focada em doen\u00e7as raras que transforma dados cl\u00ednicos e gen\u00e9ticos do mundo real em informa\u00e7\u00f5es acion\u00e1veis para pacientes, m\u00e9dicos e empresas farmac\u00eauticas, anunciou hoje que ela e certos acionistas vendedores iniciaram uma oferta p\u00fablica subscrita de 3.500.000 a\u00e7\u00f5es ordin\u00e1rias da Companhia, sendo 2.000.000 a\u00e7\u00f5es ordin\u00e1rias oferecidas pela Companhia e 1.500.000 a\u00e7\u00f5es ordin\u00e1rias oferecidas pelos acionistas vendedores. Al\u00e9m disso, os acionistas vendedores esperam conceder aos subscritores uma op\u00e7\u00e3o de 30 dias para adquirir at\u00e9 525.000 a\u00e7\u00f5es ordin\u00e1rias adicionais ao pre\u00e7o da oferta p\u00fablica, menos os descontos e comiss\u00f5es de subscri\u00e7\u00e3o. A oferta est\u00e1 sujeita \u00e0s condi\u00e7\u00f5es de mercado e outras condi\u00e7\u00f5es, e n\u00e3o h\u00e1 garantia de que a oferta ser\u00e1 conclu\u00edda, nem quando, ou ainda sobre o tamanho ou os termos reais da oferta.<\/p>\n<p>O Credit Suisse e o SVB Leerink atuam como coordenadores conjuntos da oferta proposta, com o Baird, o BTIG e a Kempen &amp; Co atuando como co-coordenadores.<\/p>\n<p>A CENTOGENE pretende utilizar os recursos l\u00edquidos da oferta para pesquisa e desenvolvimento, visando apoiar o desenvolvimento de medicamentos \u00f3rf\u00e3os com sua plataforma de informa\u00e7\u00f5es baseada em conhecimento, bem como para capital de giro e outras finalidades corporativas gerais. Uma parte dos recursos l\u00edquidos tamb\u00e9m poder\u00e1 ser utilizada para adquirir ou investir em neg\u00f3cios, ativos ou tecnologias complementares.<\/p>\n<p>A oferta est\u00e1 sendo realizada exclusivamente por meio de um prospecto. C\u00f3pias do prospecto preliminar relativo \u00e0 oferta poder\u00e3o ser obtidas, quando dispon\u00edveis, gratuitamente, acessando o EDGAR no site da Comiss\u00e3o de Valores Mobili\u00e1rios dos EUA (\u201cSEC\u201d) em www.sec.gov. Alternativamente, c\u00f3pias do prospecto preliminar, quando dispon\u00edveis, poder\u00e3o ser obtidas junto \u00e0 Credit Suisse Securities (USA) LLC, aos cuidados do Departamento de Prospectos, 6933 Louis Stephens Drive, Morrisville, NC 27560, pelo telefone (800) 221-1037 ou pelo e-mail usa.prospectus@credit-suisse.com; ou junto \u00e0 SVB Leerink LLC, aos cuidados do Departamento de Sindicato, One Federal Street, 37\u00ba andar, Boston, MA 02110, pelo telefone (800) 808-7525, ramal 6218 ou pelo e-mail [endere\u00e7o de e-mail omitido]. syndicate@svbleerink.com .<\/p>\n<p>Um pedido de registro relativo \u00e0 oferta foi protocolado na SEC, mas ainda n\u00e3o entrou em vigor. Os t\u00edtulos n\u00e3o podem ser vendidos nem podem ser aceitas ofertas de compra antes da data em que o pedido de registro entrar em vigor.<\/p>\n<p>Este comunicado de imprensa n\u00e3o constitui uma oferta de venda ou uma solicita\u00e7\u00e3o de oferta de compra destes t\u00edtulos, nem haver\u00e1 qualquer venda destes t\u00edtulos em qualquer estado ou jurisdi\u00e7\u00e3o em que tal oferta, solicita\u00e7\u00e3o ou venda seja ilegal antes do registro ou qualifica\u00e7\u00e3o de acordo com as leis de valores mobili\u00e1rios de tal estado ou jurisdi\u00e7\u00e3o.<\/p>\n<h2 class=\"h3\">Sobre a CENTOGENE<strong> <\/strong><\/h2>\n<p>A CENTOGENE dedica-se ao diagn\u00f3stico e \u00e0 pesquisa de doen\u00e7as raras, transformando dados cl\u00ednicos e gen\u00e9ticos do mundo real em informa\u00e7\u00f5es pr\u00e1ticas para pacientes, m\u00e9dicos e empresas farmac\u00eauticas. Nosso objetivo \u00e9 trazer racionalidade \u00e0s decis\u00f5es de tratamento e acelerar o desenvolvimento de novos medicamentos \u00f3rf\u00e3os, utilizando nosso amplo conhecimento em doen\u00e7as raras, incluindo dados epidemiol\u00f3gicos e cl\u00ednicos, bem como biomarcadores inovadores. A CENTOGENE desenvolveu uma plataforma global propriet\u00e1ria para doen\u00e7as raras, baseada em nosso reposit\u00f3rio de dados do mundo real, com aproximadamente 3 bilh\u00f5es de pontos de dados ponderados de mais de 530.000 pacientes representando mais de 120 pa\u00edses diferentes, em 31 de mar\u00e7o de 2020.<\/p>\n<p>A plataforma da empresa inclui dados epidemiol\u00f3gicos, fenot\u00edpicos e gen\u00e9ticos que refletem uma popula\u00e7\u00e3o global, al\u00e9m de um biobanco de amostras de sangue desses pacientes. A CENTOGENE acredita que esta \u00e9 a \u00fanica plataforma capaz de analisar de forma abrangente dados em m\u00faltiplos n\u00edveis para aprimorar a compreens\u00e3o de doen\u00e7as heredit\u00e1rias raras, o que pode auxiliar na identifica\u00e7\u00e3o de pacientes e melhorar a capacidade de nossos parceiros farmac\u00eauticos de lan\u00e7ar medicamentos \u00f3rf\u00e3os no mercado. Em 31 de mar\u00e7o de 2020, a empresa colaborava com 39 parceiros farmac\u00eauticos, abrangendo mais de 45 doen\u00e7as raras diferentes.<\/p>\n<h5>Contato com a m\u00eddia<strong> <\/strong><\/h5>\n<p>CENTOGENE<br \/> Sun Kim<br \/> Diretor(a) de Estrat\u00e9gia e Rela\u00e7\u00f5es com Investidores<br \/> <a href=\"mailto:investor.relations@centogene.com\" title=\"Escreva um e-mail\">investor.relations@centogene.com<\/a><\/p>\n<p>Consultoria FTI<br \/> Bridie Lawlor<br \/> +1.917.929.5684<br \/> <a href=\"mailto:bridie.lawlor@fticonsulting.com\" title=\"Escreva um e-mail\">bridie.lawlor@fticonsulting.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (Globe Newswire) &#8211; Centogene N.V. (Nasdaq: CNTG), a commercial-stage company [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2338","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pt\/a-centogene-anuncia-proposta-de-oferta-publica-primaria-e-secundaria-de-acoes-ordinarias\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (Globe Newswire) &#8211; Centogene N.V. (Nasdaq: CNTG), a commercial-stage company [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pt\/a-centogene-anuncia-proposta-de-oferta-publica-primaria-e-secundaria-de-acoes-ordinarias\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-08T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares\",\"datePublished\":\"2020-07-08T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\"},\"wordCount\":643,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\",\"name\":\"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2020-07-08T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pt\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE anuncia proposta de oferta p\u00fablica prim\u00e1ria e secund\u00e1ria de a\u00e7\u00f5es ordin\u00e1rias | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pt\/a-centogene-anuncia-proposta-de-oferta-publica-primaria-e-secundaria-de-acoes-ordinarias\/","og_locale":"pt_BR","og_type":"article","og_title":"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CENTOGENE","og_description":"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (Globe Newswire) &#8211; Centogene N.V. (Nasdaq: CNTG), a commercial-stage company [&hellip;]","og_url":"https:\/\/www.centogene.com\/pt\/a-centogene-anuncia-proposta-de-oferta-publica-primaria-e-secundaria-de-acoes-ordinarias\/","og_site_name":"CENTOGENE","article_published_time":"2020-07-08T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"admincg","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares","datePublished":"2020-07-08T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/"},"wordCount":643,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/","url":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/","name":"CENTOGENE anuncia proposta de oferta p\u00fablica prim\u00e1ria e secund\u00e1ria de a\u00e7\u00f5es ordin\u00e1rias | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2020-07-08T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Orientando a Medicina de Precis\u00e3o","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pt\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts\/2338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/comments?post=2338"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts\/2338\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/media?parent=2338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/categories?post=2338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/tags?post=2338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}